Ketogenic dietary therapies (KDTs) are well-established, non-pharmacologic treatments used for children and adults with medication-refractory or drug-resistant epilepsy (DRE) [1], but they also represent the mainstay of treatment for glucose transporter type 1 deficiency syndrome (GLUT1-DS, OMIM 606777) [2]. This evidence concerns the gene SLC2A1 and epilepsy.